Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 4Multiple Myeloma 3Melanoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligometastatic Disease 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Burkitt Lymphoma 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Tretinoin × Clear all
NCT04303169 2025-10-27

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
146 enrolled
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04305041 2025-08-29

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
100 enrolled
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03200847 2024-10-01

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

University of Colorado, Denver

Phase 1/2 Completed
26 enrolled 13 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡